The Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) initiative will enroll up to 13,500 adults aged 30 and over in a Phase 3 clinical trial to evaluate whether certain drugs approved for other conditions safely and effectively treat mild-to-moderate COVID-19, the National Institutes of Health announced yesterday. 

With funding from the American Rescue Plan Act, the ACTIV-6 trial will test up to seven drugs administered orally or by inhaler at home, with a focus on enrolling patients in minority, rural and other communities significantly affected by COVID-19. 

“While we’re doing a good job with treating hospitalized patients with severe disease, we don’t currently have an approved medication that can be self-administered to ease symptoms of people suffering from mild disease at home, and reduce the chance of their needing hospitalization,” said NIH Director Francis Collins, M.D. “ACTIV-6 will evaluate whether certain drugs showing promise in small trials can pass the rigor of a larger trial.”
 

Related News Articles

Headline
The Federal Emergency Management Agency is reminding stakeholders that funding is available under FEMA’s Public Assistance program, including for…
Headline
The Centers for Medicare & Medicaid Services today released an interim final rule requiring long-term care facilities in the Medicare and Medicaid…
Headline
The Department of the Treasury yesterday released an interim final rule implementing $350 billion in American Rescue Plan Act funding to help state, local…
Headline
The Food and Drug Administration today announced the expansion of its emergency use authorization for Pfizer’s COVID-19 vaccine to include adolescents ages 12…
Headline
Learn what design and engineering changes are under consideration by hospital and health system leaders like Bradley Pollitt, vice president of facilities at…
Headline
Illinois health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence in…